AE Analysis Finds Low Rate of T-Cell Malignant Neoplasms in CAR T Recipients

Only 11 cases of adverse events (AEs) were reported over a 6-year time frame, the investigators found, following administration of chimeric antigen receptor T-cell therapy (CAR T).

Related Keywords

,Novartis ,Event Reporting System ,Kite Pharma ,Image Credit ,Chimeric Antigen Receptort Cell Therapy ,Car T ,Jama Oncology ,